Founded in Lawrence, United States, CritiTech, Inc. is dedicated to the research and development of fine-particle compounds, primarily for Active Pharmaceutical Ingredient (API) production and coatings. The company's core mission is to enhance drug development processes and improve patient outcomes through innovative particle technology. CritiTech serves pharmaceutical companies across the United States, offering specialized Contract Development and Manufacturing Organization (CDMO) services to help clients bring their drugs to market efficiently.
CritiTech has garnered attention for its cutting-edge approach to drug development, attracting partnerships with notable pharmaceutical firms. The company's achievements include successful collaborations that have led to improved drug formulations and delivery systems. By focusing on fine-particle technology, CritiTech has made a significant impact on the pharmaceutical industry, contributing to the advancement of more effective and accessible medications.
